Molecules involved in USP8/EGFR and TR4 signaling pathways as well as selective inhibitors of HSP90 are emerging as attractive therapeutic targets, especially as no ideal treatment exists for treating corticotroph adenomas not cured by surgery, possibly paving the way for personalized medicine in the future. This evidence concerns the gene EGFR and ACTH-producing pituitary gland adenoma.